PRLD
Prelude Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$357.61M
P/E Ratio
—
EPS
$-1.00
Beta
1.01
52W High
$5.54
52W Low
$0.75
50-Day MA
$4.35
200-Day MA
$2.59
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Prelude Therapeutics Inc
Prelude Therapeutics Incorporated, a precision clinical-stage oncology company, focuses on the discovery and development of small molecule therapies optimized to target key drivers in cancers. The company is headquartered in Wilmington, Delaware.
Fundamentals
| Revenue (TTM) | $16.72M |
| Gross Profit (TTM) | $16.72M |
| EBITDA | $-81.17M |
| Operating Margin | -309.50% |
| Return on Equity | -95.30% |
| Return on Assets | -39.70% |
| Revenue/Share (TTM) | $0.21 |
| Book Value | $0.95 |
| Price-to-Book | 5.45 |
| Price-to-Sales (TTM) | 21.39 |
| EV/Revenue | 15.78 |
| EV/EBITDA | -0.54 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 41.00% |
| Shares Outstanding | $64.92M |
| Float | $27.59M |
| % Insiders | 13.80% |
| % Institutions | 64.32% |
Historical Volatility
HV 10-Day
99.12%
HV 20-Day
79.81%
HV 30-Day
78.27%
HV 60-Day
112.93%
HV Rank
—
Volatility is currently expanding
Analyst Ratings
Consensus ($8.00 target)
1
Strong Buy2
BuyMore HEALTHCARE Stocks
Data last updated: 6/13/2026